Treating lung fibroblasts or epithelial cells with TGF-β in vitro can replicate some key pathological features observed in idiopathic pulmonary fibrosis (IPF) patients, including increased extracellular matrix (ECM) deposition and abnormal cell proliferation (2). The gene discussed is TGFB1; the disease is pulmonary fibrosis.